Research Briefings

Blossom has joined forces with Report on Psychedelics to produce a bi-weekly briefing on psychedelic research. Each briefing recaps the latest psychedelic research in easy to understand language. The briefings aim to help grow the impact of psychedelic research and accurately represent findings to a wider audience.

How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I'll focus on the flexible repeated dosing in a trial with psilocybin for depression.
The risks of microdosing, challenging experience of psychedelics, and the promise of short-lasting DMT for TRD.
Investigating psychedelics in trials that we haven't seen there before (ayahuasca and ibogaine), plus the psychological factors in MDMA-assisted therapy
Exploring psychedelic therapy: Beyond drugs, integrating psychotherapy and context for personality changes and mental health benefits.
Explore the latest in psychedelic research: cost-effective group therapy models, unique effects of 5-MeO-DMT, and personality changes post-experience.
Psychedelic Science 2023 slides from Blossom's Floris Wolswijk on the history & outlook of psychedelic science
In the Research Briefing 1) a closer look at psychedelics as a tool to explore the depths of consciousness, 2) using psychedelics to explore creativity, a look at the brainwaves, 3) predicting & maximising the mystical experience.
In the Research Briefing of March 15th: 1) LSD safe to give in a novel, cost-effective, therapeutic framework, 2) Can you distinguish LSD from psilocybin, a new study says no, 3) The challenges ahead for psychedelics as medicine
In the Research Briefing of February 14th: 1) Flashbacks are common in psychedelic research but participants don't seem to mind 2) LSD influences creativity, breaking down thought patterns and relocating them toward the new 3) Psychedelics and society; thought on the past, present and future
In the Research Briefing of January 24th: 1) Ketamine effective in abstaining from alcohol for up to 6 months later 2) Real-world data provides further evidence ketamine therapy is effective for depression 3) But a large study finds ketamine not to be effective for PTSD in service members

Research Briefings

Blossom has joined forces with Report on Psychedelics to produce a bi-weekly briefing on psychedelic research. Each briefing recaps the latest psychedelic research in easy to understand language. The briefings help you make sense of the latest psychedelic research through explanation and adding context to research papers.

Recent briefings are also accompanied by an audio recording that is released on the podcast channel of Report on Psychedelics.

Understand the latest psychedelic research with our bi-weekly research briefing.